A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability – a vital step in the development of new medicines – is being rolled out by scientists from the UK’s University of Bath through their spin-out company, BLOC Labs.
The tool, launched this week, will help researchers identify the most promising protein molecules for drug development. It has the potential to play an important role in the creation of monoclonal antibodies (mAbs). The market for these therapeutic antibodies is worth over £70 billion.
Monoclonal antibodies are a type of protein derived from natural antibodies and then refined and mass produced in the lab. They are steadily transforming the way we treat and prevent diseases, from cancer and conditions affecting the immune system to viral infections. [Read more…] about Technology that predicts protein stability is released by UK university spin-out company